Replies to post #153052 on Biotech Values

[mcbio]

GILD is down slightly on today’s POSITRON data, but that’s not surprising, IMO. The phase-3 results in genotype-2/3 were not better than expected, and a lot of value is already baked into GILD’s share price for the HCV program.

Was the data maybe even a little disappointing? Also, to what extent does this data incorporate cirrhotic patients?